NEW YORK – Etiome launched on Thursday as a new company developing targeted therapeutics for serious and progressive chronic diseases with unmet needs, starting with metabolic, neurodegenerative, precancerous, and autoimmune conditions.
Venture capital company Flagship Pioneering backed Etiome's launch with an initial commitment of $50 million, which Etiome will use to advance its Temporal Biodynamics platform and develop an initial pipeline of preventive, targeted medicines. Flagship Pioneering has invested in companies including Foghorn Therapeutics, Moderna, and Sana Biotechnology.
"Etiome is redefining how we think about disease progression and developing interventions precisely designed for critical intervention windows, at the earliest stages of disease," Raj Panjabi, board director of Etiome, said in a statement. He's also a senior partner and head of Flagship Pioneering's Preemptive Health and Medicine Initiative, which launched Etiome.
Cambridge, Massachusetts-based Etiome's Temporal Biodynamics platform uses artificial intelligence to analyze clinical, cellular, and molecular data.
With the platform, Etiome aims to characterize underlying disease biology and differentiate between stages of disease progression. The company is betting it can use this information to predict a patient's likelihood of progressing further into disease and develop drugs that halt or reverse progression by targeting biomarkers specific to the disease stage.